{"id":"leo-80190","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site pain"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3545074","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting phosphodiesterase 4, LEO 80190 increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory mediators such as TNF-α and IL-23. This mechanism reduces skin inflammation and is designed for topical treatment of inflammatory skin conditions.","oneSentence":"LEO 80190 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:31.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT00691002","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-05","conditions":"Psoriasis Vulgaris","enrollment":1245},{"nctId":"NCT01007591","phase":"PHASE3","title":"A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-10","conditions":"Psoriasis Vulgaris","enrollment":40},{"nctId":"NCT00704262","phase":"PHASE2","title":"Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-05","conditions":"Psoriasis Vulgaris","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LEO 80190","genericName":"LEO 80190","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LEO 80190 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}